Denosumab - Biologic Drug Details

Summary for denosumab

Tradenames:	2
High Confidence Patents:	10
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for denosumab

Recent Clinical Trials for denosumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Taiwan University Hospital, Yun-Lin Branch	PHASE4
Peking Union Medical College Hospital	NA
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	PHASE1

See all denosumab clinical trials

Pharmacology for denosumab

Mechanism of Action	RANK Ligand Blocking Activity
Established Pharmacologic Class	RANK Ligand Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for denosumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for denosumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,167,492	2035-12-01	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,421,987	2038-07-18	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,513,723	2034-12-09	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for denosumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,006,091	2033-06-06	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,016,338	2036-12-20	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,047,398	2031-10-05	Patent claims search

International Patents for denosumab

Country	Patent Number	Estimated Expiration
Denmark	2270052
Australia	2018226416
Norway	345566

Supplementary Protection Certificates for denosumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
45/2010	Austria		PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 MITTEILUNG 20100528
CA 2010 00031	Denmark
SPC/GB10/043	United Kingdom		PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR))(HUMAN MONOCLONAL AMG 162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG 162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526

Market Dynamics and Financial Trajectory for Denosumab

Last updated: March 12, 2026

Denosumab is a monoclonal antibody biologic approved for treating osteoporosis, bone metastases, and other bone-related conditions. Its commercial and clinical landscape reflects evolving demand, competitive pressures, pricing strategies, and regulatory developments.

Market Overview

Denosumab is marketed under the brand name Prolia for osteoporosis and Xgeva for bone metastases. It is developed by Amgen and marketed globally by Amgen and other partners. The drug's mechanism involves inhibiting RANKL (Receptor Activator of Nuclear factor Kappa-Β Ligand), reducing bone resorption.

Global sales reached approximately $4.4 billion in 2021, with growth driven by expanding indications and increasing osteoporosis prevalence among aging populations.

Key Market Drivers and Constraints

Drivers

• Aging Population: The increased incidence of osteoporosis among individuals aged 60 and above sustains demand.
• Expanded Indications: Approval for cancer metastases and surgical prevention expands revenue streams.
• Clinical Efficacy: Demonstrates superior fracture risk reduction over bisphosphonates in certain populations.
• Patient and Provider Preference: Subcutaneous administration (dose every 6 months for osteoporosis) enhances compliance.

Constraints

• High Cost: Per-use pricing approximates $1,200 for osteoporosis treatment, impacting payer adoption.
• Bilateral Competition: Bisphosphonates and emerging oral RANKL inhibitors challenge market share.
• Safety Concerns: Rare risks like osteonecrosis of the jaw and atypical femoral fractures influence prescribing.

Competitive Landscape

Product	Mechanism	Approved Indications	Market Share (2022)	Pricing Strategy
Denosumab	RANKL inhibitor	Osteoporosis, bone metastases	70%	Premium pricing, cost for osteoporosis ~$1,200/annual dose
Zoledronic acid	Bisphosphonate	Osteoporosis, cancer-related	20%	Lower per-dose cost
Others	Various	Limited	10%	Competitive, often off-patent

Revenue Trajectory and Forecasting

Sales peaked in 2021 at approximately $4.4 billion. Market growth is projected at approximately 5% annually through 2027, driven by:

• Rising osteoporosis prevalence, especially in Asia-Pacific regions.
• Broader adoption in oncology indications.
• Patent protections extending into the late 2020s and early 2030s for primary formulations.

Key Factors Affecting Financial Outlook

• Patent Expiry: Main patents expire between 2027-2030; biosimilar entrants could erode revenue.
• Pricing Trends: Cost containment measures and biosimilar competition could reduce average selling prices.
• Regulatory Approvals: New indications or formulations may boost sales; delays could suppress growth.

Revenue Projection Summary (2022-2030)

Year	Projected Revenue ($ billion)	Growth Rate	Key Assumptions
2022	4.4	—	Baseline, full-year sales
2023	4.6	4.5%	Continued penetration, stable pricing
2025	5.0	4-5%	Expanded indications, emerging biosimilar competition
2027	4.7	-6%	Patent expiry, biosimilar entry begins
2030	3.8	-20%	Biosimilar proliferation reduces revenue

Pricing and Cost Considerations

Pricing strategies aim to balance premium valuation with payer sensitivity. Loss of exclusivity could depress prices by 20-40%, depending on biosimilar market entry timing.

Regulatory and Policy Environment

Regulatory guidelines for biosimilar approval and substitution vary globally, impacting market entry and competition timelines. Governments increasingly emphasize cost-effective therapies, potentially limiting revenue growth.

Mergers, Acquisitions, and R&D Pipeline

• Pipeline: Developing next-generation RANKL inhibitors and oral formulations.
• Acquisitions: Amgen's strategy includes partnerships with biosimilar producers to mitigate patent risks.
• Investments: Focus on expanding indications, including rheumatoid arthritis and oncological uses.

Key Takeaways

• Denosumab maintains a significant market position owing to clinical efficacy and convenience.
• Revenue growth faces challenges from patent expiries and biosimilar competition beginning late 2020s.
• Pricing strategies and market expansion in emerging regions are critical for sustaining financial trajectory.
• Future growth depends on regulatory approvals for new indications and formulations.

FAQs

1. When are denosumab patents set to expire?
Main patents expire between 2027 and 2030; biosimilar competition is expected shortly after.

2. What biosimilar entrants are approved or imminent?
Several biosimilars are approved in markets like the European Union and Australia; U.S. biosimilar filings are underway.

3. How does denosumab compare with bisphosphonates in efficacy?
Denosumab often shows superior fracture risk reduction in high-risk populations but at a higher cost.

4. What impact could biosimilars have on denosumab's revenue?
Potential erosion of up to 50% of sales post-biosimilar entry in mature markets.

5. Are there ongoing clinical developments for denosumab?
Yes. Ongoing research explores alternative formulations, new indications, and combined therapies.

---

References

[1] Amgen Inc. (2022). Prolia and Xgeva Sales Data. Amgen Financial Reports.
[2] EvaluatePharma. (2022). Biologic Drug Market Analysis.
[3] FDA. (2021). Biologics License Application Approvals.
[4] European Medicines Agency. (2022). Biosimilar Approvals and Guidelines.
[5] IQVIA. (2022). Global Oncology Biosimilar Market Forecasts.